Recent Updates
Recently added Catalysts
ICLR Positive Sentiment Score: 65/100

ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call DUBLIN--(BUSINESS WIRE)

Key Takeaway: ICON plc has announced the schedule for its fourth quarter and full year 2023 earnings conference call, set for February 22, 2024. The financial results will be disclosed after market closure on February 21, 2024. This announcement underscores ICON's commitment to transparency with its stakeholders. The company is poised to share insights and updates on its performance alongside future expectations amidst market uncertainties.

Market Sentiment Analysis

POSITIVE FACTORS

  • ICON plc will release its financial results, reflecting potential growth.
  • The company is proactive in communicating upcoming events to investors.
  • As a leading organization, ICON is pivotal in advancing clinical research.

CONCERNS & RISKS

  • The forward-looking statements are subject to numerous risks and uncertainties.
  • Actual results may differ significantly from those announced due to market conditions.
  • Dependencies on new contracts and client relationships present potential vulnerabilities.

Full Press Release Details

ICON plc Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call

DUBLIN--(BUSINESS WIRE)--January 30, 2024--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the fourth quarter and
full year 2023 results after the market closes on Wednesday, February 21, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 22, 2024 at 8:00am ET.
Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following
the conclusion of the call.
ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government
and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 106 locations in 53 countries as at
September 30, 2023. For further information about ICON, visit: www.iconplc.com.
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not
guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties
and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new
offices and offering of new services, the integration of new business mergers and acquisitions, the impact of COVID-19 on our business, as well as other economic and global market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation
to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

Contacts

Vice President Investor Relations

Frequently Asked Questions

When will ICON plc release its Q4 2023 financial results?

ICON plc will release its Q4 and full year 2023 results on February 21, 2024.

What time is the ICON plc earnings call scheduled?

The earnings call is scheduled for February 22, 2024, at 8:00 am ET.

Where can I find the webcast replay of the call?

The webcast replay will be available about an hour after the call on the website.

How many employees does ICON plc have?

As of September 30, 2023, ICON plc employed approximately 41,150 people.

What does ICON plc specialize in?

ICON plc specializes in healthcare intelligence and clinical research services.

Last updated: Jan 30, 2024